

Wright Medical Group N.V.
Supplemental Net Sales Information
(unaudited)

Three months ended September 24, 2017 net sales growth/(decline)

Product line	<u>U.S. as reported</u>	<u>Int'l constant currency</u>	<u>Int'l as reported</u>	<u>Global constant currency</u>	<u>Global as reported</u>
Lower extremities	0%	(4%)	(2%)	(1%)	(1%)
Upper extremities	19%	18%	22%	19%	20%
Biologics	2%	7%	10%	3%	4%
Sports med & other	0%	6%	9%	4%	6%
Total net sales	7%	8%	11%	8%	8%

Nine months ended September 24, 2017 net sales growth/(decline)

Product line	<u>U.S. as reported</u>	<u>Int'l constant currency</u>	<u>Int'l as reported</u>	<u>Global constant currency</u>	<u>Global as reported</u>
Lower extremities	1%	(6%)	(8%)	0%	(1%)
Upper extremities	15%	8%	7%	13%	13%
Biologics	6%	13%	12%	8%	8%
Sports med & other	(7%)	4%	1%	0%	(2%)
Total net sales	8%	4%	2%	6%	6%

Wright Medical Group N.V.
Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share
(dollars in thousands, except per share data--unaudited)

	Three months ended		Nine months ended	
	September 24, 2017	September 25, 2016	September 24, 2017	September 25, 2016
Net loss from continuing operations, as reported	\$ (34,122)	\$ (52,709)	\$ (91,789)	\$ (134,932)
Net loss from continuing operations per share, as reported	\$ (0.33)	\$ (0.51)	\$ (0.88)	\$ (1.31)
Reconciling items:				
Inventory step-up amortization	—	10,306	—	30,922
Non-cash interest expense on convertible notes ¹	11,494	10,516	33,743	25,812
Non-cash loss on extinguishment of debt	—	—	—	12,343
Derivatives mark-to-market adjustments ²	(199)	(3,187)	(4,163)	(26,460)
Transaction and transition costs	3,311	8,105	9,485	27,952
Management changes	—	—	—	1,348
CVR mark-to-market adjustments ²	4,485	2,243	6,721	8,968
Contingent consideration fair value adjustment ²	133	70	309	376
Legal settlement	—	—	—	1,800
Costs associated with 2021 Notes issuance	—	—	—	234
Tax benefit related to realizability of net operating losses	(8,928)	—	(8,928)	—
IRS settlement ³	—	—	—	(3,073)
Tax effect of reconciling items ⁴	—	(2,313)	(70)	(5,634)
Non-GAAP net loss from continuing operations, as adjusted	\$ (23,826)	\$ (26,969)	\$ (54,692)	\$ (60,344)
Add back amortization of intangible assets	7,178	7,466	21,574	21,407
Adjusted non-GAAP earnings	\$ (16,648)	\$ (19,503)	\$ (33,118)	\$ (38,937)
Weighted-average basic shares outstanding	104,836	103,072	104,292	102,854
Adjusted non-GAAP earnings per share	\$ (0.16)	\$ (0.19)	\$ (0.32)	\$ (0.38)

¹ Impacting interest expense, net

² Impacting other expense (income), net

³ IRS Settlement includes \$0.8 million of interest income and \$2.3 million tax benefit.

⁴ Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended		Nine months ended	
	September 24, 2017	September 25, 2016	September 24, 2017	September 25, 2016
Net loss from continuing operations	\$ (34,122)	\$ (52,709)	\$ (91,789)	\$ (134,932)
Interest expense, net	18,978	16,795	55,512	41,673
Benefit from income taxes	(8,822)	(2,325)	(7,498)	(6,913)
Depreciation	15,000	14,885	42,124	41,005
Amortization	7,178	7,466	21,574	21,407
Non-GAAP EBITDA	\$ (1,788)	\$ (15,888)	\$ 19,923	\$ (37,760)
Reconciling items impacting EBITDA:				
Non-cash share-based compensation expense	5,445	3,528	14,131	9,901
Other expense (income), net	5,457	(365)	6,875	(3,494)
Inventory step-up amortization	—	10,306	—	30,922
Transaction and transition costs	3,311	8,105	9,485	27,952
Management changes	—	—	—	1,348
Legal settlement	—	—	—	1,800
Costs associated with 2021 Notes issuance	—	—	—	234
Non-GAAP adjusted EBITDA	\$ 12,425	\$ 5,686	\$ 50,414	\$ 30,903
Net sales from continuing operations	170,503	157,332	527,387	497,339
Non-GAAP adjusted EBITDA margin	7.3%	3.6%	9.6%	6.2%

Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations
(dollars in thousands--unaudited)

	Three months ended		Nine months ended	
	September 24, 2017	September 25, 2016	September 24, 2017	September 25, 2016
Gross profit from continuing operations, as reported	\$ 132,082	\$ 111,183	\$ 413,718	\$ 355,515
Gross margins from continuing operations, as reported	77.5 %	70.7 %	78.4 %	71.5 %
Reconciling items impacting gross profit:				
Inventory step-up amortization	—	10,306	—	30,922
Transaction and transition costs	1,310	1,573	1,995	3,651
Non-GAAP gross profit from continuing operations, as adjusted	\$ 133,392	\$ 123,062	\$ 415,713	\$ 390,088
Net sales from continuing operations	170,503	157,332	527,387	497,339
Non-GAAP adjusted gross margins from continuing operations	78.2%	78.2%	78.8%	78.4%

Wright Medical Group N.V.
Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results

(dollars in thousands--unaudited)

	Three months ended		Nine months ended	
	September 24, 2017	September 25, 2016	September 24, 2017	September 25, 2016
Net sales	\$ 170,503	\$ 157,332	\$ 527,387	\$ 497,339
Selling, general and administrative expense, as reported	\$ 131,421	\$ 129,840	\$ 392,073	\$ 401,069
Selling, general and administrative expense as a percentages of net sales, as reported	77.1 %	82.5 %	74.3 %	80.6 %
Reconciling items impacting selling, general and administrative expense:				
Transaction and transition costs - selling, general and administrative	1,878	6,382	7,267	23,913
Management changes	—	—	—	1,348
Legal settlement	—	—	—	1,800
Costs associated with 2021 Notes issuance	—	—	—	234
Selling, general and administrative expense, as adjusted	\$ 129,543	\$ 123,458	\$ 384,806	\$ 373,774
Selling, general and administrative expense as a percentage of net sales, as adjusted	76.0%	78.5%	73.0%	75.2%
Research & development expense, as reported	\$ 11,992	\$ 12,481	\$ 36,971	\$ 36,705
Research & development expense as a percentages of net sales, as reported	7.0 %	7.9 %	7.0 %	7.4 %
Reconciling items impacting research & development expense:				
Transaction and transition costs - research & development	122	150	222	389
Research & development expense, as adjusted	\$ 11,870	\$ 12,331	\$ 36,749	\$ 36,316
Research & development expense as a percentage of net sales, as adjusted	7.0%	7.8%	7.0%	7.3%